Roche immunotherapy cocktail boosts survival in liver cancer

ZURICH: Roche's Tecentriq immunotherapy mixed with the older cancer drug Avastin lifted both overall survival and progression-free survival in people with liver cancer that cannot be surgically removed, the Swiss drugmaker said on Monday.

The company said it plans to submit the data to health authorities including the U.S. Food and Drug Administration, the European Medicines Agency and the China National Medical Products Administration, in hopes of a speedy approval in this new indication.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Patients can talk to cancer coaches about treatment options and lifestyle issuesSINGAPORE - When Ms Naruemon Saekhow, 46, was diagnosed with breast cancer in July last year, she needed to talk to someone about the torrent of questions flooding her mind.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »

Staying on guard against skin cancer
Source: TODAYonline - 🏆 1. / 99 Read more »